Literature DB >> 23881415

Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's disease.

Luis Quintino1, Giuseppe Manfré, Erika Elgstrand Wettergren, Angrit Namislo, Christina Isaksson, Cecilia Lundberg.   

Abstract

Glial cell line-derived neurotrophic factor (GDNF) has great potential to treat Parkinson's disease (PD). However, constitutive expression of GDNF can over time lead to side effects. Therefore, it would be useful to regulate GDNF expression. Recently, a new gene inducible system using destabilizing domains (DD) from E. coli dihydrofolate reductase (DHFR) has been developed and characterized. The advantage of this novel DD is that it is regulated by trimethoprim (TMP), a well-characterized drug that crosses the blood-brain barrier and can therefore be used to regulate gene expression in the brain. We have adapted this system to regulate expression of GDNF. A C-terminal fusion of GDNF and a DD with an additional furin cleavage site was able to be efficiently regulated in vitro, properly processed and was able to bind to canonical GDNF receptors, inducing a signaling cascade response in target cells. In vivo characterization of the protein showed that it could be efficiently induced by TMP and it was only functional when gene expression was turned on. Further characterization in a rodent model of PD showed that the regulated GDNF protected neurons, improved motor behavior of animals and was efficiently regulated in a pathological setting.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23881415      PMCID: PMC3863791          DOI: 10.1038/mt.2013.169

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  40 in total

1.  Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression.

Authors:  Martine Latta-Mahieu; Magali Rolland; Catherine Caillet; Manping Wang; Philippe Kennel; Irene Mahfouz; Isabelle Loquet; Jean-François Dedieu; Abderrahim Mahfoudi; Emanuelle Trannoy; Vincent Thuillier
Journal:  Hum Gene Ther       Date:  2002-09-01       Impact factor: 5.695

2.  Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys.

Authors:  David N Hovland; Robert B Boyd; Mark T Butt; Jeffery A Engelhardt; Michael S Moxness; Mark H Ma; Maurice G Emery; Nadia B Ernst; Randall P Reed; Jillynne R Zeller; Don M Gash; Donna M Masterman; Beth M Potter; Mary E Cosenza; Ruth M Lightfoot
Journal:  Toxicol Pathol       Date:  2007-12       Impact factor: 1.902

3.  A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules.

Authors:  Laura A Banaszynski; Ling-Chun Chen; Lystranne A Maynard-Smith; A G Lisa Ooi; Thomas J Wandless
Journal:  Cell       Date:  2006-09-08       Impact factor: 41.582

4.  Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.

Authors:  Biljana Georgievska; Deniz Kirik; Carl Rosenblad; Cecilia Lundberg; Anders Björklund
Journal:  Neuroreport       Date:  2002-01-21       Impact factor: 1.837

5.  α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons.

Authors:  Mickael Decressac; Banafsheh Kadkhodaei; Bengt Mattsson; Ariadna Laguna; Thomas Perlmann; Anders Björklund
Journal:  Sci Transl Med       Date:  2012-12-05       Impact factor: 17.956

6.  Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity.

Authors:  Fredric P Manfredsson; Nihal Tumer; Benedek Erdos; Tessa Landa; Christopher S Broxson; Layla F Sullivan; Aaron C Rising; Kevin D Foust; Yi Zhang; Nicholas Muzyczka; Oleg S Gorbatyuk; Philip J Scarpace; Ronald J Mandel
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

7.  Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications.

Authors:  R Gleckman; N Blagg; D W Joubert
Journal:  Pharmacotherapy       Date:  1981 Jul-Aug       Impact factor: 4.705

8.  Pharmacokinetics of trimethoprim in the rat.

Authors:  Y H Tu; L V Allen; V M Fiorica; D D Albers
Journal:  J Pharm Sci       Date:  1989-07       Impact factor: 3.534

9.  Chemical control of protein stability and function in living mice.

Authors:  Laura A Banaszynski; Mark A Sellmyer; Christopher H Contag; Thomas J Wandless; Steve H Thorne
Journal:  Nat Med       Date:  2008-09-28       Impact factor: 53.440

10.  FACS binding assay for analysing GDNF interactions.

Authors:  Luís Quintino; Aurélie Baudet; Jonas Larsson; Cecilia Lundberg
Journal:  J Neurosci Methods       Date:  2013-05-10       Impact factor: 2.390

View more
  20 in total

1.  A Drug-Tunable Gene Therapy for Broad-Spectrum Protection against Retinal Degeneration.

Authors:  Clayton P Santiago; Casey J Keuthan; Sanford L Boye; Shannon E Boye; Aisha A Imam; John D Ash
Journal:  Mol Ther       Date:  2018-07-19       Impact factor: 11.454

2.  Simultaneous Control of Endogenous and User-Defined Genetic Pathways Using Unique ecDHFR Pharmacological Chaperones.

Authors:  Prerana Ramadurgum; DaNae R Woodard; Steffi Daniel; Hui Peng; Prema L Mallipeddi; Hanspeter Niederstrasser; Melina Mihelakis; Viet Q Chau; Peter M Douglas; Bruce A Posner; John D Hulleman
Journal:  Cell Chem Biol       Date:  2020-04-23       Impact factor: 8.116

Review 3.  How to Train a Cell-Cutting-Edge Molecular Tools.

Authors:  Jakub Czapiński; Michał Kiełbus; Joanna Kałafut; Michał Kos; Andrzej Stepulak; Adolfo Rivero-Müller
Journal:  Front Chem       Date:  2017-03-10       Impact factor: 5.221

Review 4.  AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models.

Authors:  Katrina Albert; Merja H Voutilainen; Andrii Domanskyi; Mikko Airavaara
Journal:  Genes (Basel)       Date:  2017-02-08       Impact factor: 4.096

5.  Ultrasound-Triggered Effects of the Microbubbles Coupled to GDNF Plasmid-Loaded PEGylated Liposomes in a Rat Model of Parkinson's Disease.

Authors:  Peijian Yue; Wang Miao; Lin Gao; Xinyu Zhao; Junfang Teng
Journal:  Front Neurosci       Date:  2018-04-06       Impact factor: 4.677

6.  A Destabilizing Domain Allows for Fast, Noninvasive, Conditional Control of Protein Abundance in the Mouse Eye - Implications for Ocular Gene Therapy.

Authors:  Shyamtanu Datta; Marian Renwick; Viet Q Chau; Fang Zhang; Emily R Nettesheim; Daniel M Lipinski; John D Hulleman
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-10-01       Impact factor: 4.799

7.  Destabilizing Domains Enable Long-Term and Inert Regulation of GDNF Expression in the Brain.

Authors:  Luis Quintino; Angrit Namislo; Marcus Davidsson; Ludivine S Breger; Patrick Kavanagh; Martino Avallone; Erika Elgstrand-Wettergren; Christina Isaksson; Cecilia Lundberg
Journal:  Mol Ther Methods Clin Dev       Date:  2018-09-04       Impact factor: 6.698

Review 8.  GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease.

Authors:  Xavier d'Anglemont de Tassigny; Alberto Pascual; José López-Barneo
Journal:  Front Neuroanat       Date:  2015-02-13       Impact factor: 3.856

9.  A regulatable AAV vector mediating GDNF biological effects at clinically-approved sub-antimicrobial doxycycline doses.

Authors:  Abdelwahed Chtarto; Marie Humbert-Claude; Olivier Bockstael; Atze T Das; Sébastien Boutry; Ludivine S Breger; Bep Klaver; Catherine Melas; Pedro Barroso-Chinea; Tomas Gonzalez-Hernandez; Robert N Muller; Olivier DeWitte; Marc Levivier; Cecilia Lundberg; Ben Berkhout; Liliane Tenenbaum
Journal:  Mol Ther Methods Clin Dev       Date:  2016-03-30       Impact factor: 6.698

10.  Striatonigral neurons divide into two distinct morphological-physiological phenotypes after chronic L-DOPA treatment in parkinsonian rats.

Authors:  T Fieblinger; L Zanetti; I Sebastianutto; L S Breger; L Quintino; M Lockowandt; C Lundberg; M A Cenci
Journal:  Sci Rep       Date:  2018-07-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.